Kfar-Sava, Israel Clinical Trials

A listing of Kfar-Sava, Israel clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 45 clinical trials
Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

Myelofibrosis (MF) is a bone marrow illness that affects blood-forming tissues in the body. MF disturbs the body's normal production of blood cells, causing extensive scarring in the bone marrow. This leads to severe anemia, weakness, fatigue, and an enlarged spleen. The purpose of this study is to see how …

Sheba Medical Center /ID# 222151
 (9.0 away) Contact site
  • 15 views
  • 01 Aug, 2021
  • +27 other locations
Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitdine With or Without Venetoclax in Participants With Myelodysplastic Syndrome

Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, with a very low survival rate and few options for participants who are unable to undergo intensive chemotherapy, the current standard of care. This study is to evaluate how safe lemzoparlimab (TJ011133) is and how it moves within …

venetoclax
myeloid leukemia
ejection fraction
blast cells
azacitidine
Rabin Medical Center /ID# 227738
 (6.6 away) Contact site
  • 0 views
  • 25 Jun, 2021
  • +33 other locations
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

The primary purpose of this study is to determine: the recommended Phase 2 doses (RP2Ds) of JNJ-64264681 and JNJ 67856633 when administered together in participants with B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) (Part A - Dose Escalation); and the safety of the RP2Ds for this combination …

chronic lymphocytic leukemia
lymphoma
leukemia
Sheba Medical Center
 (9.0 away) Contact site
  • 0 views
  • 26 Jul, 2021
  • +32 other locations
Study to Evaluate Adverse Events Change in Disease Activity Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers

B-cell cancer is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The main objective of this study is to evaluate the safety and efficacy of ABBV-623 and ABBV-992 given alone and in combination in treating B-cell cancers. Adverse events, …

btk inhibitor
cancer
mantle cell lymphoma
b-cell lymphoma
large b-cell lymphoma
Sheba Medical Center /ID# 226754
 (9.0 away) Contact site
  • 0 views
  • 03 Jun, 2021
  • +17 other locations
Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)

The purpose of this study is to assess the safety and pharmacokinetics of MK-5890 when administered alone and in combination with pembrolizumab (MK-3475) in adults with advanced solid tumors. The initial course of MK-5890 monotherapy or MK-5890 plus pembrolizumab combination therapy will be for up to 35 administrations (approximately 2 …

carboplatin
paclitaxel
cancer
cancer chemotherapy
mk-3475
The Chaim Sheba Medical Center - Oncology Institute ( Site 0001)
 (9.0 away) Contact site
  • 283 views
  • 02 Aug, 2021
  • +11 other locations
A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

The purpose of this study is to determine the recommended Phase 2 dose regimen or the maximum tolerated dose of JNJ-67856633 in participants with relapsed/ refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

beta human chorionic gonadotrophin
lymphoid leukemia
b-cell lymphoma
chronic lymphocytic leukemia
hodgkin's disease
Sheba Medical Center
 (9.0 away) Contact site
  • 81 views
  • 01 Aug, 2021
  • +46 other locations
Evaluation of Pain Reduction in the Administration of Saline Injections by the Usage of Pneumatic Skin Flattening

Each participant will be administered 2 injections of saline - the first in the right gluteal area and the second in the left gluteal area. Both injections will be administered intra-muscularly by the same clinician. One injection will be given with vacuum (Pneumatic Skin Flattening or PSF Machine) and the …

Emergency Department- Tel-Aviv Sourasky Medical Center
 (9.7 away) Contact site
  • 1 views
  • 07 Nov, 2020
  • 1 location
Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)

The purposes of this study are to: 1) assess the safety and tolerability and 2) establish a preliminary recommended Phase 2 dose (RP2D) and/or a maximum tolerated dose (MTD) or a maximum administered dose (MAD) of MK-2118 when administered via intratumoral (IT) injection as monotherapy and in combination with pembrolizumab …

t-cell lymphoma
immunodeficiency
metastatic malignant solid tumor
lymphoma
mk-3475
Sheba Medical Center ( Site 0301)
 (9.0 away) Contact site
  • 440 views
  • 27 Jan, 2021
  • +7 other locations
Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies

This is a study of treatment with TBX-3400 in subjects with solid malignant tumors that are resistant or refractory to standard therapies. The subject's own blood cells are exposed to a protein that has been shown in the laboratory to result in anti-tumor activity. The study hypothesis is that TBX-3400 …

Rabin Medical Center
 (6.6 away) Contact site
  • 0 views
  • 14 May, 2021
  • 1 location
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors

This is a dose escalation, MTD expansion (Phase 1b) and cohort expansions (Phase 2) study to assess the safety and tolerability of a combination of NAP with durvalumab in subjects with selected advanced or metastatic solid tumors.

major surgery
medi4736
durvalumab
anticoagulants
measurable disease
Sheba Medical Center
 (9.0 away) Contact site
  • 0 views
  • 26 Jan, 2021
  • +2 other locations